替雷利珠单抗治疗非小细胞肺癌的疗效  

The Efficacy of Terrezolizumab in the Treatment of Non-small Cell Lung Cancer

作　　者：孙军[1] 郑皆红 杨俊昌[1] SUN Jun;ZHENG Jiehong;YANG Junchang(Jianhu County People's Hospital,Jianhu,Jiangsu,224700,China)

机构地区：[1]建湖县人民医院,江苏建湖224700

出　　处：《中外医疗》2025年第7期5-8,共4页China & Foreign Medical Treatment

基　　金：江苏医药职业学院课题(20229JH29)。

摘　　要：目的探讨替雷利珠单抗治疗非小细胞肺癌患者的疗效。方法便利选取2020年1月—2023年12月建湖县人民医院收治的非小细胞肺癌患者72例为研究对象,按不同治疗方案分为对照组(n=36,常规化疗)和观察组(n=36,常规化疗+替雷利珠单抗)。对两组疗效、血清肿瘤标志物水平、免疫功能与不良反应进行对比。结果与对照组的52.78%(19/36)、77.78%(28/36)对比,观察组客观缓解率77.78%(28/36)、疾病控制率97.22%(35/36)更高,差异均有统计学意义(χ^(2)=4.963,4.571;P均<0.05)。治疗后,观察组癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、鳞状细胞癌抗原水平、白细胞分抗原(cluster of differentiation,CD)8^(+)水平低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,差异均有统计学意义(P均<0.05)。在不良反应方面,两组比较,差异无统计学意义(P>0.05)。结论替雷利珠单抗治疗非小细胞肺癌可获取良好效果,可降低肿瘤标志物水平,同时调节患者的机体免疫力,且治疗不良反应较少。Objective To investigate the efficacy of terrezolizumab in the treatment of patients with non-small cell lung cancer.Methods A total of 72 patients with non-small cell lung cancer admitted to Jianhu County People's Hospital from January 2020 to December 2023 were convenient selected and divided into control group(n=36,conventional chemotherapy)and observation group(n=36,conventional chemotherapy+tirelizumab)according to different treatment regimens.The efficacy,serum tumor markers level,immune function and adverse reactions of the two groups were compared.Results Compared with the control group of 52.78%(19/36)and 77.78%(28/36),the objective remission rate of the observation group was 77.78%(28/36)and the disease control rate was 97.22%(35/36),which were higher,the differences were statistically significant(χ^(2)=4.963,4.571;both P<0.05).After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment antigen 21-1,squamous cell carcinoma antigen and the level of cluster of differentiation(CD)8^(+)in the observation group were lower than those in the control group,and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those in the control group,the differences were statistically significant(all P<0.05).In terms of adverse reactions,there was no significant difference between the two groups(P>0.05).Conclusion Tirelizumab can achieve good results in the treatment of non-small cell lung cancer,which can reduce the level of tumor markers,regulate the body immunity of patients,and has fewer adverse reactions.

关 键 词：替雷利珠单抗 非小细胞肺癌 肿瘤标记物 免疫能力 

分 类 号：R734.2[医药卫生—肿瘤]